The New England journal of medicine, 2019-03, Vol.380 (13), p.1201-1213
- Nunn, Andrew J
- Phillips, Patrick P.J
- Meredith, Sarah K
- Chiang, Chen-Yuan
- Conradie, Francesca
- Dalai, Doljinsuren
- van Deun, Armand
- Dat, Phan-Thuong
- Lan, Ngoc
- Master, Iqbal
- Mebrahtu, Tesfamarium
- Meressa, Daniel
- Moodliar, Ronelle
- Ngubane, Nosipho
- Sanders, Karen
- Squire, Stephen Bertel
- Torrea, Gabriela
- Tsogt, Bazarragchaa
- Rusen, I.D
2019
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Nunn, Andrew J
- Phillips, Patrick P.J
- Meredith, Sarah K
- Chiang, Chen-Yuan
- Conradie, Francesca
- Dalai, Doljinsuren
- van Deun, Armand
- Dat, Phan-Thuong
- Lan, Ngoc
- Master, Iqbal
- Mebrahtu, Tesfamarium
- Meressa, Daniel
- Moodliar, Ronelle
- Ngubane, Nosipho
- Sanders, Karen
- Squire, Stephen Bertel
- Torrea, Gabriela
- Tsogt, Bazarragchaa
- Rusen, I.D
- Titel
- A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis
- Ist Teil von
- The New England journal of medicine, 2019-03, Vol.380 (13), p.1201-1213
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2019
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Globally, there are more than 500,000 new infections with drug-resistant tuberculosis each year. In this trial involving patients with rifampin-resistant tuberculosis, a shorter, more intense course of treatment (9 to 11 months) was found to be noninferior to a standard 20-month regimen.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1811867Titel-ID: cdi_proquest_journals_2213911046
- Format
- –
- Schlagworte
- Adult, AIDS-Related Opportunistic Infections - drug therapy, AIDS-Related Opportunistic Infections - mortality, Antibiotics, Antitubercular Agents - administration & dosage, Antitubercular Agents - adverse effects, Clinical trials, Drug Administration Schedule, Drug dosages, Drug Therapy, Combination, Female, Fluoroquinolones, HIV, Human immunodeficiency virus, Humans, Intention to Treat Analysis, Kaplan-Meier Estimate, Male, Medication Adherence, Middle Aged, Moxifloxacin, Moxifloxacin - administration & dosage, Moxifloxacin - adverse effects, Multidrug resistance, Multidrug resistant organisms, Rifampin, Tuberculosis, Tuberculosis, Multidrug-Resistant - drug therapy, Tuberculosis, Multidrug-Resistant - mortality, Tuberculosis, Pulmonary - drug therapy